FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> bimatoprost | Allergan

Allergan eyes billion-dollar mascara market

Move over mascara. Allergan announced today that it will be filing a new drug application for bimatoprost, a drug that it claims encourages eyelash growth. It expects sales in excess of $500 million per year--modest expectations in light of the estimated $3.7 billion per year mascara market. Allergan makes Lumigan, a glaucoma remedy that had the unusual added benefit of promoting eyelash growth. Some doctors were prescribing it off-lable for its cosmetic use, and Allergan has struck out at cosmetic companies for producing an OTC products they say are based partly on Lumigan ingredients.

Bimatoprost, a synthetic prostaglandin analog, results in eyelash growth that is significant when applied directly to the eyelash bases, according to Allergan's clinical trials. The company expects FDA to approve the drug in 2009.

- read the news in the WSJ
- s
ee MarketWatch for more

Related Articles:
Allergan, FDA fight eyelash-mad copycats
Allergan wins FDA OK for new therapy
Allergan injects $370M into Esprit buyout

Bookmark and Share
Get Your FREE FiercePharma Email Newsletter:
Comments (3) | Post a comment
More stories about bimatoprost   Allergan  

Comments

I am an instructor at two universities in Indianaolis. One of my students has glaucoma. She treats her glaucoma with drops, and she has the longest, prettiest eyelashes. I believe you! Please send me information ASAP when this is marketed. Incidentally, I have glaucoma in my family, so I am hoping for the best when I go see my opthamologist.

how do you get to participate in one of their clinical studies in nc?

It sounds great, please email when it would be available.

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.